KeyBanc raised the firm’s price target on Encompass Health (EHC) to $117 from $115 and keeps an Overweight rating on the shares. The firm says Q3 results look really strong, highlighted by a 4% EBITDA beat driven by stronger SS volumes. KeyBanc continues to favor Encompass Health’s stock given strong fundamentals and insulation from election-related dynamics.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHC: